Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
YARDLEY, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2023, and provided operational updates.
- We are pleased with the progress we made in the third quarter towards our 2023 operating objectives while sharply reducing expenses.
- Today’s results show that we are outperforming our initial expectations for 2023 XHANCE net revenues while operating far more efficiently and preparing our organization for a successful launch in 2024.
- Previously, the Company expected XHANCE net revenues for the full year of 2023 to be between $64.0 to $70.0 million.
- Members of the Company’s leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.